Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Treasury Shares (2018 - 2025)

IGC Pharma has reported Treasury Shares over the past 8 years, most recently at $6.5 million for Q3 2025.

  • Quarterly Treasury Shares fell 11.77% to $6.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Sep 2025, down 11.77% year-over-year, with the annual reading at $5.8 million for FY2025, 22.22% down from the prior year.
  • Treasury Shares was $6.5 million for Q3 2025 at IGC Pharma, roughly flat from $6.5 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $8.5 million in Q2 2023 and troughed at $173000.0 in Q1 2021.
  • The 5-year median for Treasury Shares is $5.9 million (2022), against an average of $5.7 million.
  • Year-over-year, Treasury Shares tumbled 90.65% in 2021 and then surged 3322.54% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $5.8 million in 2021, then fell by 0.63% to $5.8 million in 2022, then soared by 47.26% to $8.5 million in 2023, then dropped by 14.77% to $7.3 million in 2024, then decreased by 10.79% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Treasury Shares are $6.5 million (Q3 2025), $6.5 million (Q2 2025), and $5.8 million (Q1 2025).